Continuous Glucose Monitoring (CGM) Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Rising Prevalence of Diabetes and Earlier Diagnosis

Diagnosis can bring CGM into the care pathway earlier when the patient has a monitoring need that the technology can address. The International Diabetes Federation projects that the global number of adults with diabetes will reach 853 million by 2050. The American Diabetes Association's 2026 Standards of Care recommend CGM at diabetes onset and thereafter for people who could benefit from it in diabetes management.^[1] The projection describes a larger prospective patient pool, while the recommendation gives clinicians an entry point for monitoring within diabetes care. For clinicians following that guidance, selecting CGM can become part of the initial treatment decision for an eligible newly diagnosed patient.

Rapid Uptake of Remote Monitoring and Tele-Health Integration

Telehealth integration can support repeat CGM demand by making coverage follow-up possible without an exclusively in-person care pathway. Medicare requires the treating practitioner to conduct an in-person or Medicare-approved telehealth visit every 6 months after the initial CGM prescription to document adherence to the CGM regimen and diabetes treatment plan. The documentation requirement ties continued coverage to a clinical assessment beyond the initial prescription. A remote visit preserves that assessment while allowing the beneficiary to complete it without an office trip. A patient who cannot readily attend a clinic can therefore meet the review requirement remotely and retain a route to covered sensor refills.

Sensor Miniaturization and Accuracy Breakthroughs

Fewer sensor changes can make sustained CGM use more manageable for eligible adults, strengthening the case for adoption. In 2025, Dexcom Inc. launched G7 15 Day in the United States with a new algorithm that the company described as delivering its best sensor accuracy to date. The FDA cleared the modification on April 9, 2025, extending wear to 15 days for users aged 18 and older. Dexcom attributed fewer sensor changes to the longer wear period, giving users a practical benefit alongside the new algorithm. The 18-and-older clearance directs this usability proposition toward adult adoption, giving suppliers a defined population for the longer-wear product.

Favorable Reimbursement Expansion in OECD & China

Public reimbursement supports CGM demand by defining a patient group whose devices and continuing supplies qualify for coverage. Medicare Part B covers CGMs, sensors and transmitters when the prescription follows FDA indications and the patient uses insulin or has a history of problematic hypoglycemia. Eligibility also requires a doctor visit within 6 months of ordering to evaluate diabetes control and confirm the coverage criteria. From May 1, 2025, Saskatchewan provided full coverage of continuous and flash glucose monitors for eligible insulin-treated adults aged 18 to 25 and 65 and older. The Canadian expansion targets specified adult cohorts, while Medicare illustrates how coverage extends to continuing supplies. Converting this funding into device demand therefore starts with documenting the eligible patient and the indicated prescription.

High Device and Consumable Costs for Payers And Patients

A prescription does not become a CGM purchase when coverage denial leaves the patient unable to pay. An April 2025 report by the American Diabetes Association and NORC described a U.S. Medicaid focus-group participant who could not afford a prescribed CGM after insurance denied coverage and continued traditional blood glucose monitoring. This experience places reimbursement between clinical intent and the supplier's ability to convert that intent into device demand. For patients facing the same financial constraint, a recommendation alone cannot resolve the affordability gap that prevents use. The commercial limit is therefore an unfilled prescription, with the monitoring benefit contingent on financing the patient can actually access.

Calibration / Data-Overload Usability Concerns

Excess glucose information can constrain both initial CGM acceptance and the willingness to continue wearing a device. A survey at one Los Angeles County federally qualified health center from November 2023 to February 2025 found 31.3% of 16 never-users declining clinician-recommended CGM did not want excess glucose information. Among 18 former users answering the discontinuation question, 50% cited too many alarm notifications as a reason for stopping.^[2] These findings identify separate commercial losses, since reluctance can prevent a first purchase while alarm burden can interrupt continued demand. More frequent information can therefore become a usability cost that weakens the case for sustained wear among patients with these concerns.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Continuous Glucose Monitoring (CGM) Market Segment Analysis

Sensors held 89.35% of revenue in 2026 and are the largest and fastest-growing segment, with a projected CAGR of 15.36% from 2027 to 2032. In January 2026, Abbott Laboratories reported public-program funding for its FreeStyle Libre 3 Plus sensor in every Canadian province, subject to eligibility and program terms.^[3] This gives the sensor business a geographically broad route to publicly financed demand within Canada. The commercial mechanism depends on qualifying patients reaching the funded product through their respective programs. Abbott's public-program reach in every Canadian province gives rival sensor suppliers a reimbursement benchmark alongside device performance.

Transmitters fall within Medicare's supply allowance for adjunctive CGMs, where CMS includes sensors and transmitters and denies separate billing as unbundling. That treatment makes the supplied system's reimbursement economics more relevant than a separate transmitter billing opportunity for this patient group. Receivers have a distinct coverage role because Medicare covers the CGM supply allowance only when the beneficiary uses a durable medical equipment receiver or insulin infusion pump to display glucose data, although a non-DME device may also be used alongside it. These rules make the covered display pathway and the bundled supply allowance important to commercial participation, preserving hardware roles that a smartphone-only view of monitoring would overlook.

Home and personal use accounted for a 73.62% share of the continuous glucose monitoring (CGM) market size in 2026, making it the largest segment. Separately, Abbott Laboratories reported in September 2026 that more than 8 million people across over 60 countries used its Libre portfolio. Abbott's U.S. FreeStyle Libre setup instructions say the sensor should be removed or replaced after 15 days. Each replacement cycle turns continued personal monitoring into demand for another sensor, giving the supplier an opportunity for repeat sales beyond the initial device purchase.

Hospitals and clinics form the fastest-growing segment, with a projected CAGR of 18.05% from 2027 to 2032. Spring Grove Hospital Center's May 2025 policy directed staff to use Dexcom G7 for eligible patients with diabetes and to follow manufacturer guidance and hospital protocols. It assigned supply ordering to the clinic RN manager or designee, with a purchase request submitted to the Finance Department. The policy shows one state hospital placing CGM inside a defined clinical and purchasing workflow, with named responsibility for ordering supplies.

Adult users represented a 65.35% continuous glucose monitoring (CGM) market share in 2026, making adults the largest segment. The American Diabetes Association's 2026 Standards recommend CGM for older adults with type 1 diabetes and older adults with type 2 diabetes on insulin, with evidence grades A and B, respectively. The recommendation targets improved glycemic outcomes, reduced hypoglycemia and lower treatment burden, connecting monitoring to specific care needs in these older cohorts. The type 2 recommendation's insulin condition makes treatment regimen a more precise basis for targeting older adult users than age alone.

The pediatric segment is the fastest-growing segment, with a projected CAGR of 17.85% from 2027 to 2032. On June 12, 2026, the FDA cleared Dexcom's Stelo integrated CGM for over-the-counter use by people aged 2 and older who do not use insulin. Children must use it under adult caregiver supervision, and the system is not intended for people with problematic hypoglycemia or people on dialysis. Nonprescription availability changes the access route by allowing eligible families to obtain the system without a prescription. The supervising caregiver is a necessary participant for suppliers to reach, even when the child is the wearer.

Geography Analysis

North America Continuous Glucose Monitoring (CGM) Market

North America held a 50.55% continuous glucose monitoring (CGM) market share in 2026, making it the largest geography. Dexcom Inc. generated USD 3.33 billion in U.S. CGM-system revenue in 2025, with U.S. revenue growing 15% year over year. Its U.S. distributor revenue substantially exceeded its direct-channel revenue in 2025, placing intermediaries at the center of the company's sales model in the country. In the United States, this established sales base makes channel execution commercially consequential, since a large operating business already connects monitoring systems with buyers through both routes.

Asia-Pacific Continuous Glucose Monitoring (CGM) Market

Asia-Pacific is the fastest-growing geography, with a projected CAGR of 15.78% from 2027 to 2032. In 2025, MicroTech Medical reported adding registrations and market access for its LinX continuous glucose monitoring system in India. Separately, India's Central Government Health Scheme classifies 2-week CGM as a laboratory investigation in its revised rate schedule effective October 13, 2025, applying to services at empaneled providers and to reimbursement claims by eligible beneficiaries. The schedule gives eligible beneficiaries a payer pathway for provider-delivered monitoring alongside the product registrations. Device suppliers can pursue sales through added product access, while empaneled providers can earn service revenue from eligible monitoring episodes.

Europe's public-access route is illustrated by United Kingdom NHS guidance that CGM should be available to anyone with type 1 diabetes, with children usually offered real-time systems and adults a real-time or flash choice. Middle East and Africa also contains public procurement routes, illustrated by Bahrain's 2025 tender for 2-year CGM supply and installation, with 6 bids recorded at opening. In South America, Brazil's Conitec held a consultation on real-time CGM for type 1 diabetes for SUS coverage, which closed on August 17, 2026. That assessment places the public-coverage decision between clinical need and a potential purchasing route. Suppliers face different commercial tasks in these examples, serving eligible NHS users, competing for Bahrain's tender or awaiting Brazil's coverage decision.

Regulatory Framework and Outlook

This comparison of selected jurisdictions assesses policy attractiveness from the perspective of a CGM manufacturer seeking commercial market access. United States special controls for Class II integrated CGM (iCGM) systems require accuracy evidence, secure data-transmission validation and manufacturing controls that ensure performance specifications are met. The United States Quality Management System Regulation (QMSR), effective February 2, 2026, incorporates ISO 13485:2016 for covered device manufacturers. The commercial comparison therefore turns on the evidence, quality systems and authorization steps attached to the supplier's particular product.

United States iCGM validation and quality-system duties and the EU's mandatory EUDAMED modules, which apply in Germany, support medium ratings, while proposed FY 2028-2032 United States review goals and the EU's pending December 2025 burden-reduction proposal support easing subject to further legislation. China's registration and lifecycle quality duties underpin medium attractiveness, with strengthened medical-device good manufacturing practice (GMP) requirements effective November 1, 2026 supporting hardening. Brazil's medium rating reflects class-based registration under RDC 751/2022, and the planned 2026-2027 review of separate SaMD rules supports continuity for sensor-hardware entry because agenda work leaves that class-based route operative. Saudi Arabia's medium rating reflects a premarket gate with specified exceptions, and the SFDA's August 2026 dual glucose-ketone authorization supports continuity because the innovation pathway operates within that requirement.

Value Chain Stages

The value chain compares device manufacturing, system integration and distribution as distinct sources of supplier earnings. Abbott Laboratories manufactures Libre portfolio products in Kilkenny, Ireland. Medtronic plc, whose diabetes business is now MiniMed Group, Inc., announced a February 2026 European launch pairing Simplera sensor and InPen smart insulin pen data in one app. These roles place value in making and integrating the monitoring product, while downstream earnings depend on a functioning distribution route.

Abbott identified contracted U.S. DME suppliers as direct purchasers in May 2026, alongside its separate authorized wholesale routes. That distinction gives distribution resilience a concrete basis, because direct supplier relationships and wholesale access offer different routes to the product. Medtronic's February 2026 announcement, for what is now MiniMed's diabetes business, specified a gradual European rollout of the combined sensor, pen and app system, so downstream sales require access to the complete configuration as it becomes available.

Key Opportunities for Market Participants

The opportunities compare newly covered clinical users with adults reachable through an expanded consumer app channel. Effective January 1, 2026, Maryland Medicaid expanded medically necessary CGM coverage to specified insulin-treated type 1 or type 2 patients, gestational-diabetes participants and people with problematic hypoglycemic events. Initial eligibility also requires a diagnosis, practitioner-confirmed training, an FDA-indicated prescription and the specified medical criteria. Separately, Abbott Laboratories made Lingo available on Android in the United States and United Kingdom in December 2025 for adults aged 18 and older who are not on insulin, with a non-diagnostic intended use.

The clinical opening turns on completing a qualified care pathway for patient groups that gained access through the Maryland expansion. Suppliers and care teams can therefore develop different onboarding approaches for insulin-treated and gestational-diabetes participants while preserving the same initial coverage requirements. The consumer opportunity requires a different proposition, since Lingo's intended use centers on eligible adults' information needs rather than diagnosis.